Abzena PLC Blocklisting update (6509T)

TIDMABZA

RNS Number : 6509T

Abzena PLC

09 January 2017

Abzena plc

Block Listing Update

Cambridge, UK, 9 January 2017 - Further to the announcement by Abzena plc (AIM: ABZA, 'Abzena' or the 'Group') on 6 July 2016, the Group announces that a total of 75,000 ordinary shares of GBP0.002 each in the share capital of the Group ('Ordinary Shares') have been issued since that date pursuant to the Group's 2013 Share Incentive Plan and admitted to trading in accordance with the block listing applied for on 7 July 2015 (the 'Block Listing'). An update in accordance with Schedule 6 of the AIM Rules for Companies is set out below.

The Group holds no shares in treasury and hence the total number of current voting rights is 137,130,555. The Group will notify on a monthly basis when there are changes to the issued share capital, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Group.

BLOCK LISTING SIX MONTHLY RETURN

 
 Name of applicant:                                    Abzena plc 
----------------------------------------------------  ---------------------------------------------------------------- 
 Name of scheme:                                       Abzena plc 2013 Share Incentive Plan 
----------------------------------------------------  ---------------------------------------------------------------- 
 Period of return:           From:                     6 July 2016                 To:        6 January 2017 
--------------------------  ------------------------  --------------------------  ---------  ------------------------- 
 Balance of unallotted securities under scheme(s) 
  from previous return:                                832,476 
----------------------------------------------------  ---------------------------------------------------------------- 
 Plus: The amount by which the block scheme(s) has     Nil 
 been increased since the date of the last 
 return (if any increase has been applied for): 
----------------------------------------------------  ---------------------------------------------------------------- 
 Less: Number of securities issued/allotted under 
  scheme(s) during period (see LR3.5.7G):              75,000 
----------------------------------------------------  ---------------------------------------------------------------- 
 Equals: Balance under scheme(s) not yet 
  issued/allotted at end of period                     757,476 
----------------------------------------------------  ---------------------------------------------------------------- 
 Number and class of securities originally admitted    1,779,000 ordinary shares of GBP0.002 each, admitted on 13 July 
 and the date of admission                             2015 
----------------------------------------------------  ---------------------------------------------------------------- 
 Name of contact:                                      Julian Smith 
----------------------------------------------------  ---------------------------------------------------------------- 
 Telephone number of contact:                          [phone] 
----------------------------------------------------  ---------------------------------------------------------------- 
 
 

Enquiries:

 
   Abzena plc 
    John Burt, Chief Executive 
    Officer Julian Smith, Chief 
    Financial Officer                  [phone] 
   Numis (Nominated Adviser and 
    Broker) 
    Clare Terlouw / James Black        [phone] 
    / Paul Gillam                       1000 
   N+1 Singer (Joint Broker)           [phone] 
    Aubrey Powell / Liz Yong            3000 
   Instinctif Partners                 [phone] 
    Melanie Toyne Sewell / Rozi         2020 
    Morris                              [e-mail] 
 

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.

The term "Abzena inside" is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on "Abzena inside" products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).

-- Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.

-- Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.

-- Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.

-- Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.

For more information, please see www.abzena.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLREANFNEDKXEEF

(END) Dow Jones Newswires

January 09, 2017 04:37 ET (09:37 GMT)